/Investor DB

Prime Movers — 2023 Investments

1 investments dated 2023 · listed companies and verified rows first · show all

Paradromicsparadromics.comin𝕏Apr 2023SEC filingmedium confidence

Paradromics develops a brain-computer interface (BCI) system, with FDA Breakthrough Device Designations for speech decoding and digital device control, and works with academic medical institutions on translational BCI research.

BiotechDeep TechHealthtechMedical DevicesAustin, US

Matt Angle(Founder and CEO)inRon Kelly(Director)Thomas Krummel(Director)Adam Kablanian(Director)

Board seatDakin Sloss· per SEC Form D · $34.6M raise · filed Apr 2023

Co-investors15th RockAlpha EdisonAnthropy PartnersATEL VenturesCapital FactoryCloudStone Capital+27 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.